Welcome to visit Huaren Pharmaceutical group


Founded in May 1998, Huaren Pharmaceutical is a modern pharmaceutical and health industry group integrating R&D, production and sales, focusing on medicine, health, medical equipment and medical services.

In August 2010, the company was successfully listed on the Shenzhen Stock Exchange, the stock abbreviation is "Huaren Pharmaceutical", stock code "300110". In July 2019, the company underwent a change of shareholding, and the management committee of Xi'an Qujiang New Area became the actual controller of the company.

After more than 20 years of development, the company's business focuses on nephrology, respiratory, fine hemp and large-volume preparations and other fields, and has successively built five production bases in Qingdao, Rizhao, Xiaogan, Pubei and Hefei, with a total production capacity of 950 million bags (bottles), and all production lines have passed the new GMP certification. The company's main products include small-volume injections, peritoneal dialysate, therapeutic infusions, basic infusions, medical devices, tablets, capsules, powders, granules, supporting drug packaging, health products and APIs, etc., with a total of 98 varieties and 212 specifications of existing drugs, realizing the integrated development of "raw materials + preparations + pharmaceutical packaging materials".

Taking innovation as the soul of development, in recent years, the company has actively grasped strategic development opportunities, focused on the treatment direction of nephrology, respiratory, fine anesthesia and the screening of new varieties such as large-volume preparations, benchmarked against first-class enterprises at home and abroad, continued to increase R&D investment, enriched R&D channels, enriched product lines, and enhanced sustainable development. By the end of 2021, Huaren Pharmaceutical and its subsidiaries had obtained a total of 457 authorized patents, including 94 invention patents. Among them, Stellar Pharmaceutical, a wholly-owned holding subsidiary, is one of the 47 designated manufacturers of Class II psychotropic APIs in China.

With mature supply chain integration capabilities, refined cost control system and perfect quality management, the company's products are widely accepted and recognized by customers, and its products have successfully entered more than 30 provinces and cities and more than 1600 hospitals in China, with a market share in the forefront. In 2021, Stellar Pharmaceutical's doxofylline injection (10ml: 0.1g) successfully won the bid for the fourth batch of national drug procurement.

In 2021, the company's operating income will be 1.561 billion yuan, a year-on-year increase of 18.55%; The net profit attributable to shareholders of the listed company was 130 million yuan, an increase of 37.81% over the same period last year; Taxes paid 183 million yuan.

Through more than 20 years of exploration and practice, the company has successively won a series of honors such as "National Key Technological Transformation 'Double High and One Excellent' Project", "National AAA Grade Credit Enterprise", "Excellent Enterprise in Shandong Pharmaceutical Industry on the 60th Anniversary of the Founding of the People's Republic of China", "Quality Management Award of Shandong Province", "Shandong Famous Brand Products", "Top 100 Industrial Enterprises in China's Chemical and Pharmaceutical Industry with Comprehensive Strength", "National Intellectual Property Advantage Demonstration Enterprise", "Excellent Product Brand of Respiratory System" and so on. In 2019, Huaren Pharmaceutical ranked 271st among the "Top 500 Brands of Chinese Listed Companies" with a brand value of 17.007 billion yuan. In 2020, the company won the honorary title of "2020 National Market Quality Credit AA (Customer Satisfaction Enterprise)" issued by China Association for Quality. In 2021, it ranked 87th in the "Top 100 Chinese Pharmaceutical Industry in 2020". On April 26, 2022, the company won the May Day Labor Award of Shandong Province.

In the future, the company will actively respond to the national "Healthy China" strategy, take product strength construction as the support, actively promote the strategic layout of pharmaceutical health through  synchronize independent research and collaborative innovation, and strive to grow into a pharmaceutical and health industry group integrating APIs, preparations, medical devices, pharmaceutical packaging materials and other sectors with comprehensive and coordinated development.